Suppr超能文献

相似文献

4
Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer.
Cancer Res. 2017 Jul 1;77(13):3527-3539. doi: 10.1158/0008-5472.CAN-16-3470. Epub 2017 May 18.
9
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Mol Cancer Ther. 2012 Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-0474. Epub 2011 Dec 21.
10
Trametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells.
J Cell Mol Med. 2020 Jun;24(12):6822-6832. doi: 10.1111/jcmm.15336. Epub 2020 Apr 30.

引用本文的文献

1
Inhibitors Targeting the F-BOX Proteins.
Cell Biochem Biophys. 2023 Dec;81(4):577-597. doi: 10.1007/s12013-023-01160-1. Epub 2023 Aug 25.
3
Tumor necrosis factor receptor-2 signaling pathways promote survival of cancer stem-like CD133 cells in clear cell renal carcinoma.
FASEB Bioadv. 2020 Jan 3;2(2):126-144. doi: 10.1096/fba.2019-00071. eCollection 2020 Feb.
5
Targeted therapies for advanced non-small cell lung cancer.
Oncotarget. 2018 Dec 25;9(101):37589-37607. doi: 10.18632/oncotarget.26428.
6
Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types.
Cell Rep. 2018 Apr 3;23(1):213-226.e3. doi: 10.1016/j.celrep.2018.03.047.
8
NVP-BKM120 inhibits colon cancer growth via FoxO3a-dependent PUMA induction.
Oncotarget. 2017 Sep 15;8(47):83052-83062. doi: 10.18632/oncotarget.20943. eCollection 2017 Oct 10.
9
Overcoming Acquired Resistance to AZD9291, A Third-Generation EGFR Inhibitor, through Modulation of MEK/ERK-Dependent Bim and Mcl-1 Degradation.
Clin Cancer Res. 2017 Nov 1;23(21):6567-6579. doi: 10.1158/1078-0432.CCR-17-1574. Epub 2017 Aug 1.

本文引用的文献

1
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations.
Mol Cancer Ther. 2012 Aug;11(8):1747-57. doi: 10.1158/1535-7163.MCT-11-1021. Epub 2012 May 31.
4
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
Mol Cancer Ther. 2012 Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-0474. Epub 2011 Dec 21.
5
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.
J Clin Oncol. 2012 Jan 20;30(3):282-90. doi: 10.1200/JCO.2011.36.1360. Epub 2011 Dec 12.
7
Quercetin-mediated Mcl-1 and survivin downregulation restores TRAIL-induced apoptosis in non-Hodgkin's lymphoma B cells.
Haematologica. 2012 Jan;97(1):38-46. doi: 10.3324/haematol.2011.046466. Epub 2011 Sep 20.
8
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7.
Nature. 2011 Mar 3;471(7336):110-4. doi: 10.1038/nature09779.
9
10
Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
Clin Cancer Res. 2011 May 15;17(10):3233-47. doi: 10.1158/1078-0432.CCR-10-2530. Epub 2011 Feb 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验